Next Phase Newsletter

A China-based VC focused exclusively on the biotech industry combines a deep understanding of drug development, industry networks, as well as regulatory expertise to help portfolio companies to achieve strategic goals efficiently. The partners of the fund have combined decades of drug industry experiences before establishing the firm in 2019. The fund invests in true innovations with a major impact on patients’ lives. The firm’s investment size can range from $1 M and up to $6 M, in which the typical size would be $3 M~$4 M. The firm is actively looking for new investment opportunities in North America and Europe. The firm can act as lead or co-investor.

Within biotech, the firm focuses on companies in pre-IND to phase II. The firm is opportunistic in all indications and willing to consider orphan indications.

The firm has no specific requirements for companies. The firm generally takes a board seat or an observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC firm based in Paris invests primarily in seed/series A with significant follow-on capability.

The firm is now investing with two funds; the first fund is dedicated to investing in companies based in the Paris region across various sectors (digital, deeptech, life science), while the second fund is dedicated to investing in Digital Health companies in Western Europe. The firm generally invests between 0.3-1.5M EUR in the initial investment, and can invest up to 2-5M EUR overall in a company, and will invest in up to 10 companies a year.

The firm invests differently from their two current funds :

– The first fund is sector agnostic, and will invest in Life Science (therapeutics, diagnostics, devices and digital health companies) in the Paris region.
– The second fund covering Western Europe is focused primarily on digital health, due to the strategic interest of the fund investors in this area (several healthcare companies)

The firm can lead or co-invest, and do frequently lead. They will take a board seat in any case – the firm is an active investor providing hands-on support to its portfolio company (Strategy, HR, Financing, …).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2020 and based in USA is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with check sizes between 5 – 10 million USD. The firm prefers to lead the financing rounds but is open to co-investing. The firm will consider opportunities globally.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, the firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises.

The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture fund focusing on the intersection between technology and life sciences is willing to invest globally, investing in seed-series A stages, but will consider series B opportunities as well. The firm will generally invest between $0.5-2M in seed stages, $3-5M in series A rounds, and may invest up to $15M over the lifetime of the investment.

The firm invests in solutions to complex problems in human and animal health. The firm partners with entrepreneurs and academic scientists across all stages of venture investing, and its investments span the full continuum of the healthcare ecosystem. Previously funded companies include a microbiome-based drug discovery platform, a company sequencing T-cell receptors to analyze immune function and a company developing a continuous monitoring system using a dermal patch.

The firm remains actively involved in companies after investing. The firm generally takes a board seat or board observer position in their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office with USA offices has a focus on the social impact as an overall investment mandate. The firm aims to fund cutting-edge therapeutics companies, through their accelerator arm while also investing in later-stage assets. The firm will invest globally. For their accelerator arm, the firm is seeking companies with pre-clinical and clinical therapeutics with a minimum initial investment of $1M-$10M, with the possibility of follow-on investments. The firm generally invests in companies with lead assets in Phase I – III clinical trials, and the amount of the allocation is based on the raise and pre-money valuation of the company.

The firm is looking for therapeutics companies, with a particular interest in biologics assets such as antibody-based technologies, cell and gene therapies. The firm mandate focused on regenerative and personalized medicine in oncology, neurodegenerative, orphan, and rare disease applications.

The firm will only consider companies that have more than two assets in the pipeline and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital / private equity firm headquartered in China manages both  US and RMB denominated funds. The firm invests in Series A rounds at $1-2M, though its sweet spot is investing $10-15M in Series B/C rounds. The firm works closely with local provincial Chinese governments, allowing them the ability to bring technology successfully into the Chinese market. The firm will generally not invest in the seed stage, and seeks opportunities globally.

The firm invests in pharmaceuticals and Class II medical devices, including an interest in 505(b)(2) repurposed compounds, as well as healthcare-related industries. The firm is interested in all therapeutic areas and in early to mid development stage companies. The firm focuses on unmet medical needs with a China market potential.

The firm does not have management team requirements. The firm will typically take a board seat post-investment, and has the capability to lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Based in Europe, a venture and growth capital firm provides expertise and funding to entrepreneurs and companies with global ambitions in life sciences and information technologies. The firm focuses on early to growth and expansion stage including spin-offs and restarts. The firm prefers to be the lead investor and possibly co-lead. The firm seeks to allocate €7-15 million (in equity) per company through subsequent rounds of investment. The firm seeks to invest in companies that are based in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm seeks to invest in medical devices and digital health. The firm is opportunistic in terms of subsectors and indications. Medical devices with a therapeutic focus are of high interest. The firm seeks growth stage companies with early sales or with products that, at minimum, have regulatory approval (CE mark) and compelling clinical data.

The firm requests a board seat in each portfolio company and generally holds a significant minority stake. The firm seeks a company with a strong management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.